Anti-Von Willebrand Factor antibody [4F9] (ab20435)

Overview

  • Product nameAnti-Von Willebrand Factor antibody [4F9]
    See all Von Willebrand Factor primary antibodies
  • Description
    Mouse monoclonal [4F9] to Von Willebrand Factor
  • Tested applicationsSuitable for: ICC/IF, Flow Cyt, IHC-Frmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    FVIII: C/vWF complex (denaturated)

Properties

Applications

Our Abpromise guarantee covers the use of ab20435 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration. PubMed: 22280443
Flow Cyt Use 2µg for 105 cells. . ab20435 has been used in flow cytometry with Jurkat cells and with platelets. The Jurkat cell line was fixed using 1% formaldehyde followed by permeabilization using a commercially-available saponin reagent for permeabilization. The platelets were fixed using 1% formaldehyde, washed and suspended in PBS without permeabilization.



ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
IHC-Fr 1/50 - 1/100.

Target

  • FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
  • Tissue specificityPlasma.
  • Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
  • Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
    Contains 4 TIL (trypsin inhibitory-like) domains.
    Contains 3 VWFA domains.
    Contains 3 VWFC domains.
    Contains 4 VWFD domains.
  • DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
  • Post-translational
    modifications
    All cysteine residues are involved in intrachain or interchain disulfide bonds.
    N- and O-glycosylated.
  • Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
  • Information by UniProt
  • Database links
  • Alternative names
    • Coagulation factor VIII antibody
    • Coagulation factor VIII VWF antibody
    • F8VWF antibody
    • Factor VIII related antigen antibody
    • von Willebrand antigen 2 antibody
    • von Willebrand antigen II antibody
    • Von Willebrand disease antibody
    • VWD antibody
    • vWF antibody
    • VWF_HUMAN antibody
    see all

Anti-Von Willebrand Factor antibody [4F9] images

  • ab20435, staining Von Willebrand Factor (green) in hMSC-TERT, hADMSC, hADSSC and hNFSSC cells by Immunocytochemistry/ Immunofluorescence.

    Cells were fixed in paraformaldehyde and permeabilized with 0.1% Triton X-100 for 10 min. After washing with PBS, cells were blocked with 3% BSA for 30 min and incubated with primary antibody at 10 µl/ml, at 4°C overnight. A FITC-conjugated goat anti-mouse polyclonal IgG (1/4000) was used as the secondary antibody.

References for Anti-Von Willebrand Factor antibody [4F9] (ab20435)

This product has been referenced in:
  • Masuda H  et al. Vasculogenic conditioning of peripheral blood mononuclear cells promotes endothelial progenitor cell expansion and phenotype transition of anti-inflammatory macrophage and T lymphocyte to cells with regenerative potential. J Am Heart Assoc 3:e000743 (2014). Read more (PubMed: 24965023) »
  • Kim E  et al. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheum 64:3809-17 (2012). IHC-Fr ; Human . Read more (PubMed: 22740338) »

See all 3 Publications for this product

Product Wall

Vielen Dank für Ihren Anruf.

Nachdem ich wie versprochen alle unsere Von Willebrand Faktor- Antikörperdaraufhin untersucht habe, ob sie möglicherweise die Bindung von Faktor VIII inhibieren können, weiß ich nicht, ob...

Read More

Merci de nous avoir contactés. Le laboratoire m'a informé que l'anticorps ab20435 a été utilisé en cytométrie en flux sur cellules Jurkat et thrombocytes. - Cellules Jurkat : fixation avec 1% formaldéhyde et perméabilisation avec une sol...

Read More

Thank you for your enqiry regarding the FACS testing of this antibody (ab20435). The flow cytometry application for this antibody is in a published reference. The full text is available free on-line at http://www.bloodjournal.org/cgi/reprint/91/2/4...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"